Eli Lilly has selected Pennsylvania as the site for a $3.5 billion anti-obesity drug manufacturing plant.[1] The historic Lehigh Valley steelmaking center will produce the promising weight loss drug retatrutide.[1] Additionally, the company is investing $5.3 billion to expand production of its diabetes drugs Mounjaro and obesity drug Zepbound in Indiana.[1] Zepbound generates over 74,800 recipes per week in the US and Mounjaro has over 300,000 recipes per week, up 48% from last year.[1] A clinical study showed that patients on Zepbound lost an average of 20% (22.8 kg) of weight, compared to 14% (15 kg) on Novo Nordisk's Wegos.[2] A greater proportion of patients on Zepbound achieved at least 25% weight loss.[2] Zepbound brought in $1.3 billion in revenue in the third quarter.[2] The plant will produce tirzepatide, the main ingredient in Mounjaro and Zepbound, and potentially other experimental obesity drugs.[1]